Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 61944 | 8.02 |
09:34 ET | 11108 | 7.98 |
09:36 ET | 25513 | 8.01 |
09:38 ET | 8018 | 8 |
09:39 ET | 66681 | 8.025 |
09:41 ET | 2600 | 8 |
09:43 ET | 91584 | 8 |
09:45 ET | 3199 | 7.94 |
09:48 ET | 19966 | 8.03 |
09:50 ET | 2789 | 8 |
09:52 ET | 10749 | 8.09 |
09:54 ET | 3639 | 8.05 |
09:56 ET | 30000 | 8.07 |
09:57 ET | 1143 | 8.11 |
09:59 ET | 20209 | 8.16 |
10:01 ET | 1318 | 8.15 |
10:03 ET | 27647 | 8.085 |
10:06 ET | 5595 | 8.13 |
10:08 ET | 1910 | 8.08 |
10:10 ET | 4371 | 8.03 |
10:12 ET | 5654 | 8.04 |
10:14 ET | 17261 | 7.96 |
10:15 ET | 10572 | 7.93 |
10:17 ET | 21593 | 7.95 |
10:19 ET | 6190 | 8.04 |
10:21 ET | 2456 | 7.995 |
10:24 ET | 16216 | 8.01 |
10:26 ET | 1900 | 8.09 |
10:28 ET | 2433 | 8.07 |
10:30 ET | 2895 | 8.04 |
10:32 ET | 4132 | 8.02 |
10:33 ET | 2300 | 8.02 |
10:35 ET | 3304 | 7.98 |
10:37 ET | 6008 | 7.95 |
10:39 ET | 20074 | 7.8501 |
10:42 ET | 14825 | 7.78 |
10:44 ET | 31753 | 7.76 |
10:46 ET | 22488 | 7.72 |
10:48 ET | 21321 | 7.71 |
10:50 ET | 5961 | 7.69 |
10:51 ET | 6319 | 7.71 |
10:53 ET | 12443 | 7.73 |
10:55 ET | 4056 | 7.726 |
10:57 ET | 3240 | 7.7199 |
11:00 ET | 6660 | 7.73 |
11:02 ET | 5013 | 7.74 |
11:04 ET | 12029 | 7.72 |
11:06 ET | 6021 | 7.74 |
11:08 ET | 5498 | 7.7599 |
11:09 ET | 2350 | 7.74 |
11:11 ET | 55243 | 7.78 |
11:13 ET | 1500 | 7.8 |
11:15 ET | 1000 | 7.77 |
11:18 ET | 4693 | 7.785 |
11:20 ET | 500 | 7.79 |
11:22 ET | 3598 | 7.7899 |
11:24 ET | 9797 | 7.8099 |
11:26 ET | 1000 | 7.79 |
11:27 ET | 603 | 7.8 |
11:29 ET | 1900 | 7.8 |
11:31 ET | 1676 | 7.77 |
11:33 ET | 3328 | 7.76 |
11:36 ET | 5075 | 7.78 |
11:38 ET | 2316 | 7.7 |
11:40 ET | 7708 | 7.79 |
11:42 ET | 913 | 7.76 |
11:44 ET | 3024 | 7.8 |
11:45 ET | 960 | 7.79 |
11:47 ET | 3774 | 7.8015 |
11:49 ET | 1249 | 7.81 |
11:51 ET | 5587 | 7.84 |
11:54 ET | 2300 | 7.83 |
11:56 ET | 1260 | 7.85 |
11:58 ET | 1409 | 7.85 |
12:00 ET | 3142 | 7.83 |
12:02 ET | 2500 | 7.86 |
12:03 ET | 400 | 7.855 |
12:05 ET | 2568 | 7.82 |
12:07 ET | 1601 | 7.84 |
12:09 ET | 7676 | 7.85 |
12:12 ET | 1101 | 7.81 |
12:14 ET | 13251 | 7.81 |
12:16 ET | 400 | 7.84 |
12:18 ET | 3218 | 7.86 |
12:20 ET | 908 | 7.86 |
12:21 ET | 1369 | 7.85 |
12:23 ET | 2732 | 7.8601 |
12:25 ET | 1300 | 7.89 |
12:27 ET | 1924 | 7.87 |
12:30 ET | 300 | 7.89 |
12:32 ET | 2664 | 7.88 |
12:34 ET | 63731 | 7.905 |
12:36 ET | 1810 | 7.92 |
12:38 ET | 3425 | 7.92 |
12:39 ET | 14477 | 7.8601 |
12:41 ET | 400 | 7.85 |
12:43 ET | 600 | 7.88 |
12:45 ET | 1400 | 7.87 |
12:48 ET | 3100 | 7.87 |
12:50 ET | 800 | 7.84 |
12:52 ET | 3000 | 7.83 |
12:54 ET | 700 | 7.84 |
12:56 ET | 4731 | 7.83 |
12:57 ET | 500 | 7.835 |
12:59 ET | 600 | 7.835 |
01:01 ET | 700 | 7.83 |
01:03 ET | 3681 | 7.825 |
01:06 ET | 2515 | 7.83 |
01:08 ET | 4141 | 7.8 |
01:10 ET | 4130 | 7.77 |
01:12 ET | 3506 | 7.78 |
01:14 ET | 6782 | 7.77 |
01:15 ET | 3021 | 7.7589 |
01:17 ET | 1800 | 7.75 |
01:19 ET | 3800 | 7.76 |
01:21 ET | 2657 | 7.75 |
01:24 ET | 7512 | 7.73 |
01:26 ET | 2828 | 7.72 |
01:28 ET | 2200 | 7.72 |
01:30 ET | 8919 | 7.75 |
01:32 ET | 14332 | 7.73 |
01:33 ET | 2832 | 7.73 |
01:35 ET | 1000 | 7.76 |
01:37 ET | 3432 | 7.78 |
01:39 ET | 2352 | 7.7679 |
01:42 ET | 9017 | 7.75 |
01:44 ET | 500 | 7.74 |
01:46 ET | 27864 | 7.74 |
01:48 ET | 9320 | 7.73 |
01:50 ET | 4645 | 7.74 |
01:51 ET | 200 | 7.74 |
01:53 ET | 1300 | 7.739 |
01:55 ET | 1307 | 7.76 |
01:57 ET | 7603 | 7.74 |
02:00 ET | 23625 | 7.7497 |
02:02 ET | 1780 | 7.72 |
02:04 ET | 500 | 7.735 |
02:06 ET | 6480 | 7.75 |
02:08 ET | 3300 | 7.74 |
02:09 ET | 600 | 7.75 |
02:11 ET | 1050 | 7.74 |
02:13 ET | 3151 | 7.76 |
02:15 ET | 1000 | 7.75 |
02:18 ET | 1938 | 7.77 |
02:20 ET | 2000 | 7.77 |
02:22 ET | 226 | 7.76 |
02:24 ET | 2854 | 7.77 |
02:26 ET | 1600 | 7.7637 |
02:27 ET | 18952 | 7.715 |
02:29 ET | 100672 | 7.72 |
02:31 ET | 2259 | 7.72 |
02:33 ET | 100 | 7.73 |
02:36 ET | 1081 | 7.72 |
02:38 ET | 1850 | 7.715 |
02:40 ET | 25551 | 7.74 |
02:42 ET | 3983 | 7.73 |
02:44 ET | 1000 | 7.72 |
02:45 ET | 1255 | 7.71 |
02:47 ET | 3295 | 7.74 |
02:49 ET | 2821 | 7.77 |
02:51 ET | 918 | 7.76 |
02:54 ET | 784 | 7.75 |
02:58 ET | 4027 | 7.75 |
03:00 ET | 1331 | 7.745 |
03:02 ET | 4957 | 7.7201 |
03:03 ET | 1622 | 7.74 |
03:05 ET | 2044 | 7.76 |
03:07 ET | 1009 | 7.75 |
03:09 ET | 9152 | 7.75 |
03:12 ET | 5175 | 7.725 |
03:16 ET | 2698 | 7.72 |
03:18 ET | 2945 | 7.71 |
03:20 ET | 10137 | 7.71 |
03:21 ET | 10157 | 7.71 |
03:23 ET | 991 | 7.72 |
03:25 ET | 537 | 7.71 |
03:27 ET | 18776 | 7.73 |
03:30 ET | 100 | 7.72 |
03:32 ET | 2225 | 7.73 |
03:34 ET | 1217 | 7.71 |
03:36 ET | 11570 | 7.715 |
03:38 ET | 25332 | 7.725 |
03:39 ET | 1937 | 7.72 |
03:41 ET | 9015 | 7.745 |
03:43 ET | 1700 | 7.745 |
03:45 ET | 10438 | 7.745 |
03:48 ET | 6995 | 7.74 |
03:50 ET | 10863 | 7.745 |
03:52 ET | 6114 | 7.74 |
03:54 ET | 8475 | 7.735 |
03:56 ET | 74092 | 7.755 |
03:57 ET | 41419 | 7.76 |
03:59 ET | 35567 | 7.77 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.6B | -46.9x | --- |
Madrigal Pharmaceuticals Inc | 6.0B | -11.9x | --- |
Viking Therapeutics Inc | 5.3B | -50.9x | --- |
Nuvalent Inc | 5.2B | -32.7x | --- |
Cytokinetics Inc | 6.1B | -9.6x | --- |
Immunitybio Inc | 5.0B | -6.4x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.5B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.98 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -46.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.